Metformin
Type 2 Diabetes
Approved/CommercialActive
Key Facts
About Granules India
Granules India is a vertically integrated pharmaceutical manufacturer with a mission to provide affordable, high-quality medicines globally. A key achievement is its leadership in producing large-volume generic drugs like Paracetamol, Metformin, and Ibuprofen, supported by its own API production, which provides significant cost and supply chain advantages. The company's strategic direction focuses on expanding its portfolio into more complex formulations, growing its presence in regulated markets like the US and Europe, and enhancing its R&D capabilities for value-added generics. Its operational efficiency and scale have made it a critical player in the global pharmaceutical supply chain.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Tirzepatide (Mounjaro) | Eli Lilly | Approved |
| Orforglipron | Eli Lilly | Phase 3 |
| Trulicity (dulaglutide) | Eli Lilly | Approved |
| Forxiga | AstraZeneca | Approved |
| siRNA GalXC-GYS2 | Novo Nordisk | Phase 1 |
| Amylin/semaglutide combination | Novo Nordisk | Phase 3 |
| Lipaglyn | Zydus Lifesciences | Approved |
| LBS-009 | Belite Bio | Preclinical |
| Jentadueto (Linagliptin/Metformin) | Yuhan | Approved |
| Nesina (Alogliptin) | Yuhan | Approved |
| Metformin & Combinations | Ipca Laboratories | Commercial |
| GSBR-1290 | Structure Therapeutics | Phase 2 |